or Try an Advanced Search...

    Technical Analysis for OCS - Oculis Holding AG

    Grade Last Price % Change Price Change
    A 12.02 0.59% 0.07
    OCS closed up 0.59 percent on Friday, April 26, 2024, on 2.07 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical OCS trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.59%
    Pocket Pivot Bullish Swing Setup 0.33%
    Volume Surge Other 0.33%
    Narrow Range Bar Range Contraction 0.33%
    Inside Day Range Contraction 0.33%
    Up 3 Days in a Row Strength 0.33%
    50 DMA Support Bullish 0.42%
    Older End-of-Day Signals for OCS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    Possible Pocket Pivot about 21 hours ago
    2x Volume Pace about 22 hours ago
    1.5x Volume Pace about 22 hours ago
    3x Volume Pace about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    OCS Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Lausanne, Switzerland.
    Classification
    Sector: Financial Services
    Industry: Shell Companies
    Keywords: Medicine Biopharmaceutical Disease Organ Systems Diabetes Ophthalmology Glaucoma Diabetic Retinopathy Macular Edema Diabetic Macular Edema Blindness Retinopathy Dry Eye Disease Ophthalmic Diseases

    Is OCS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
    Apr 11 Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
    Apr 10 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
    Apr 8 Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
    Apr 4 Oculis to Participate at Upcoming April Investor Conferences
    Apr 1 Oculis files $300M mixed securities shelf
    Mar 18 Oculis Holding reports Q4 results
    Mar 18 Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
    Feb 28 Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
    Jan 29 Oculis to Present at Upcoming February Investor Conferences
    See more OCS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.495
    52 Week Low 9.05
    Average Volume 42,709
    200-Day Moving Average 11.61
    50-Day Moving Average 11.85
    20-Day Moving Average 11.62
    10-Day Moving Average 11.94
    Average True Range 0.37
    RSI (14) 56.14
    ADX 17.31
    +DI 25.16
    -DI 14.94
    Chandelier Exit (Long, 3 ATRs) 11.33
    Chandelier Exit (Short, 3 ATRs) 11.67
    Upper Bollinger Bands 12.51
    Lower Bollinger Band 10.74
    Percent B (%b) 0.72
    BandWidth 15.21
    MACD Line 0.08
    MACD Signal Line 0.02
    MACD Histogram 0.0531
    Fundamentals Value
    Market Cap 437.95 Million
    Num Shares 36.4 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -4.47
    Price-to-Sales 510.76
    Price-to-Book 3.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.08
    Resistance 3 (R3) 12.08 12.06 12.07
    Resistance 2 (R2) 12.06 12.04 12.06 12.07
    Resistance 1 (R1) 12.04 12.04 12.05 12.04 12.06
    Pivot Point 12.02 12.02 12.03 12.02 12.02
    Support 1 (S1) 12.00 12.00 12.01 12.00 11.98
    Support 2 (S2) 11.98 12.00 11.98 11.97
    Support 3 (S3) 11.96 11.98 11.97
    Support 4 (S4) 11.96